Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) just unveiled an announcement.
Imricor Medical Systems, Inc. announced a significant milestone in the field of MRI-guided electrophysiology with the successful completion of the first ischemic ventricular tachycardia (VT) ablation performed entirely under real-time MRI guidance. This groundbreaking procedure, conducted at Amsterdam University Medical Centre, marks a critical advancement in treating complex arrhythmias and demonstrates the potential for safer and more effective ablations, even in high-risk patients with implantable cardioverter defibrillators. The achievement is expected to drive increased demand for Imricor’s technology and accelerate its adoption across Europe, as additional sites are set to join the VISABL-VT clinical trial.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc. operates in the medical technology industry, focusing on the development of MRI-compatible devices for cardiac ablation procedures. Their primary products include the Vision-MR Ablation Catheter and the NavTrac-MR Transseptal Kit, which are designed to enhance the precision and effectiveness of cardiac ablations using real-time MRI guidance.
Average Trading Volume: 251,859
Technical Sentiment Signal: Buy
For a thorough assessment of IMR stock, go to TipRanks’ Stock Analysis page.